Nanospectra Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $6.07M

  • Investors
  • 10

Nanospectra General Information

Description

Developer of tissue ablation therapies designed to maximize treatment efficacy while minimizing side effects. The company's therapies utilize optical tunability for a new class of nanoparticles called nanoshells that convert light into heat and thermally destroy solid tumors, enabling physicians to treat their patients by reducing side effects associated with surgery, radiation, and traditional focal therapies.

Contact Information

Website
www.nanospectra.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8285 El Rio Street
  • Suite 150
  • Houston, TX 77054
  • United States
+1 (713)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Nanotechnology, HealthTech, Life Sciences, Oncology
Corporate Office
  • 8285 El Rio Street
  • Suite 150
  • Houston, TX 77054
  • United States
+1 (713)

Nanospectra Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanospectra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Later Stage VC (Series C) 15-Mar-2023 $6.07M Completed Generating Revenue
16. Secondary Transaction - Private Completed Generating Revenue
15. Later Stage VC (Series B1) 05-Aug-2021 Completed Generating Revenue
14. Later Stage VC (Series B) 09-Feb-2017 Completed Generating Revenue
13. Later Stage VC (Series AA) 15-Dec-2015 Completed Generating Revenue
12. Later Stage VC (Series AA) 29-Aug-2014 Completed Generating Revenue
11. Later Stage VC (Series AA) 17-Jun-2013 Completed Generating Revenue
10. Grant 03-Aug-2010 Completed Generating Revenue
9. Later Stage VC (Series A) 05-Jan-2009 $1.5M $2.49M Completed Generating Revenue
8. Later Stage VC 03-Nov-2008 $250K $990K Completed Generating Revenue
To view Nanospectra’s complete valuation and funding history, request access »

Nanospectra Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C-1
Series C
Series B3
Series B2
Series B1
Series B 1,748,180 $0.001000 8% $1.43 $1.43 1x $1.26 7.04%
Series AA 6,866,440 $0.001000 8% $0.59 $0.59 1x $0.59 24.31%
To view Nanospectra’s complete cap table history, request access »

Nanospectra Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of tissue ablation therapies designed to maximize treatment efficacy while minimizing side effects. The compan
Biotechnology
Houston, TX
4 As of 2024

Jerusalem, Israel
 

Maastricht, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nanospectra Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alpha Tau Medical Formerly VC-backed Jerusalem, Israel
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Aurora Biopharma Angel-Backed New York, NY
TScan Therapeutics Formerly VC-backed Waltham, MA
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 30 competitors. Get the full list »

Nanospectra Patents

  • 42

    Total Documents Applications and Grants

  • Total Patents Families

  • 24

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Nanospectra Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022259509-A1 Devices and systems for ablation therapy Pending 13-Apr-2021
CA-3214935-A1 Devices and systems for ablation therapy Pending 13-Apr-2021
EP-4322877-A1 Devices and systems for ablation therapy Pending 13-Apr-2021
JP-2024514602-A Devices and systems for ablative treatment Pending 13-Apr-2021
US-20240189029-A1 Devices and systems for ablation therapy Pending 13-Apr-2021 A61B18/24
To view Nanospectra’s complete patent history, request access »

Nanospectra Executive Team (10)

Name Title Board Seat
David Jorden Chief Executive Officer, President and Board Member
Glenn Goodrich Ph.D Chief Operating Officer & Vice President of Process Development and Chemistry
Jon Schwartz Ph.D Director, Clinical Research & Project Manager
L. Blair Shamel Board Member & Strategic Consultant
Jennifer West Ph.D Co-Founder & Scientific Advisor
You’re viewing 5 of 10 executive team members. Get the full list »

Nanospectra Board Members (8)

Name Representing Role Since
Bradley Nyberg Self Board Member
Brian Pryor Self Board Member
David Bristol Jr. Self Board Observer
David Jorden Nanospectra Chief Executive Officer, President and Board Member
Kevin Smith Sirtex Medical Board Member
You’re viewing 5 of 8 board members. Get the full list »

Nanospectra Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanospectra Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sirtex Medical PE-Backed Company Minority
Science Applications International Corporation Minority
U.S. Department of Health and Human Services Government
Hawaii Angels Angel Group Minority
Houston Angel Network Angel Group Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Nanospectra FAQs

  • When was Nanospectra founded?

    Nanospectra was founded in 2002.

  • Who is the founder of Nanospectra?

    Jennifer West Ph.D, Naomi Halas Ph.D, and Daniel Watkins Ph.D are the founders of Nanospectra.

  • Who is the CEO of Nanospectra?

    David Jorden is the CEO of Nanospectra.

  • Where is Nanospectra headquartered?

    Nanospectra is headquartered in Houston, TX.

  • What is the size of Nanospectra?

    Nanospectra has 4 total employees.

  • What industry is Nanospectra in?

    Nanospectra’s primary industry is Biotechnology.

  • Is Nanospectra a private or public company?

    Nanospectra is a Private company.

  • What is the current valuation of Nanospectra?

    The current valuation of Nanospectra is .

  • What is Nanospectra’s current revenue?

    The current revenue for Nanospectra is .

  • How much funding has Nanospectra raised over time?

    Nanospectra has raised $23.4M.

  • Who are Nanospectra’s investors?

    Sirtex Medical, Science Applications International, U.S. Department of Health and Human Services, Hawaii Angels, and Houston Angel Network are 5 of 10 investors who have invested in Nanospectra.

  • Who are Nanospectra’s competitors?

    Alpha Tau Medical, Cristal Therapeutics, Aurora Biopharma, TScan Therapeutics, and NexImmune are some of the 30 competitors of Nanospectra.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »